Status:
COMPLETED
Lactate Imaging as a Tumour Biomarker
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborating Sponsors:
Cancer Research UK
Conditions:
Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some...
Eligibility Criteria
Inclusion
- Cohort 1:lymphoma patients
- minimum lesion size of 2cm
- not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone)
- Cohort 2:Colorectal patients
- metastatic disease of at least 2cm
- not pretreated
- Cohort 3:Phase 1 Drug Development
- minimum lesion size at least 2cm
- Cohort 4: Brain
- primary brain tumours receiving radiotherapy and temozolomide
- cerebral lymphoma receiving standard chemotherapy
Exclusion
- MRI incompatible metal implants
- Claustrophobia
- Inability to tolerate a 40 minute MRI scan
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01881386
Start Date
September 1 2013
End Date
September 1 2017
Last Update
January 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT